Combining Charge Density Analysis with Machine Learning Tools To Investigate the Cruzain Inhibition Mechanism by Luchi, Adriano Martín et al.
Combining Charge Density Analysis with Machine Learning Tools To
Investigate the Cruzain Inhibition Mechanism
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ABSTRACT: Trypanosoma cruzi, a flagellate protozoan
parasite, is responsible for Chagas disease. The parasite
major cysteine protease, cruzain (Cz), plays a vital role at
every stage of its life cycle and the active-site region of the
enzyme, similar to those of other members of the papain
superfamily, is well characterized. Taking advantage of
structural information available in public databases about Cz
bound to known covalent inhibitors, along with their
corresponding activity annotations, in this work, we
performed a deep analysis of the molecular interactions at
the Cz binding cleft, in order to investigate the enzyme
inhibition mechanism. Our toolbox for performing this study
consisted of the charge density topological analysis of the
complexes to extract the molecular interactions and machine learning classification models to relate the interactions with
biological activity. More precisely, such a combination was useful for the classification of molecular interactions as “active-like”
or “inactive-like” according to whether they are prevalent in the most active or less active complexes, respectively. Further
analysis of interactions with the help of unsupervised learning tools also allowed the understanding of how these interactions
come into play together to trigger the enzyme into a particular conformational state. Most active inhibitors induce some
conformational changes within the enzyme that lead to an overall better fit of the inhibitor into the binding cleft. Curiously,
some of these conformational changes can be considered as a hallmark of the substrate recognition event, which means that
most active inhibitors are likely recognized by the enzyme as if they were its own substrate so that the catalytic machinery is
arranged as if it is about to break the substrate scissile bond. Overall, these results contribute to a better understanding of the
enzyme inhibition mechanism. Moreover, the information about main interactions extracted through this work is already being
used in our lab to guide docking solutions in ongoing prospective virtual screening campaigns to search for novel noncovalent
cruzain inhibitors.
1. INTRODUCTION
Chagas disease (CD), a major health issue in Latin America, is
a neglected tropical disease caused by the flagellate protozoan
parasite Trypanosoma cruzi. According to estimates by the
World Health Organization, seven million people are chroni-
cally infected with the parasite and 7000 deaths per year are
caused by CD. Because of massive migration, the disease has
spread around the globe reaching nonendemic areas, where
health service awareness of the condition is limited.1,2
Available chemotherapy for CD includes ineffective drugs
for the chronic stage of the disease, leaving patients with only
two palliative drugs, benznidazole and nifurtimox, introduced
over 40 years ago. Furthermore, such drugs involve severe side
effects, and drug resistance has been observed in some
trypanosome strains. Thus, the discovery of new, safer, and
more effective drugs to treat CD is required.3
Cruzain (Cz), the major cysteine protease of T. cruzi is a
viable target for developing new drugs against CD because it is
essential for parasite survival in the human stage of infection.4
Currently, 27 inputs are associated to this molecular target
in the Protein Data Bank (rcsb.org) where Cz has been
cocrystallized with reversible and irreversible inhibitors.5
Thereby, Cz presents itself as an attractive target for the
development of potential therapeutics for the treatment of the
disease by employing a structure-based approach.6,7
Among Cz inhibitors, those containing a vinyl sulfone
warhead can exhibit good selectivity and a favorable
prospective development despite the irreversible nature of
inhibition. Jaishankar8 synthesized and determined the
inhibition constants against Cz of a series of vinyl sulfone
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analogues closely related to K-777, a Cz inhibitor. They
investigated how substitutions at P2 and P3 fragments of K-
777 modify the activities against Cz.
In this work, we exploited the structure−activity relationship
among the vinyl sulfone analogues described by Jaishankar8
but from a structure-based perspective, that is, through the
study of the molecular interactions at the enzyme binding site,
in order to get some clues about the enzyme inhibition
mechanism.
As a descriptor for molecular interactions in complexes of
vinyl sulfones with Cz, the charge density value at the
interaction critical point was employed. In the context of the
quantum theory of atoms in molecules (QTAIM),9 the
mapping of the gradient vector field onto the complex electron
charge density distribution gave rise to the topological
elements of charge density. Among the topological elements,
an interaction bond critical point (BCP) and the bond paths
(BPs), which connect it to the interacting atoms, are
unequivocal indicators of the existence of bonding interaction.
We have previously applied this theory to understand the
action mechanism of human dihydrofolate reductase inhib-
itors,10,11 BACE1 inhibitors,12,13 D2 dopamine receptor
ligands,14−18 sphingosine kinase 1 (Sphk1) inhibitors,19 and
HIV-1 protease flap fragments,20 among others.
QTAIM methodology allows detecting nondirectional
interactions, for example, those involving π electrons in
aromatic rings, among other weak and unusual contacts that
otherwise would be missed in a merely geometrical analysis of
the interactions.16
On the other hand, QTAIM analysis in biomolecular
complexes (unlike small complexes in the gas phase) often
gives rise to very dense and complex networks of interactions.
The task of analyzing such intricate network of interactions
becomes even more difficult when more than one of these
networks must be analyzed simultaneously, for example, to
extract structure−activity relationships from a set of Cz
complexes with several inhibitors.
Therefore, the processing of such massive amount of data
should not be done “by hand”, that is, by visual inspection of
the molecular graphs by a human operator. If so, a lot of
information “hidden” under the charge density data would be
overlooked.
Accordingly, in this work we employed machine learning
tools to automate the process of extracting information from
charge density molecular graphs and to exhaustively exploit the
charge density data.
We trained a support vector machine model with recursive
feature elimination (SVM-RFE) that was able to discriminate
between interactions present in complexes of the most active
inhibitors (active-like interactions) and those that occur in the
less active ones (inactive-like interactions).
Subsequently, the charge density-based correlation matrix
describing how interactions are related to each other among
the complexes was computed. This matrix, together with
analysis of the molecular dynamic (MD) trajectories, revealed
how interactions come into play together to trigger the enzyme
into a particular conformational state. Most active inhibitors
induce some conformational changes within the enzyme that
lead to an overall better fit of the inhibitor into the binding
cleft.
Analysis of intermolecular interactions revealed that back-
bone−backbone hydrogen bonds between the peptide-like
inhibitor and enzyme and interactions with the Leu67 residue
play a key role in proper anchoring of the inhibitor to the Cz
binding cleft. However, a quantitative structure−activity
relationship could not be derived by considering only the
intermolecular interactions between Cz residues and inhibitor
atoms.
On the other hand, if intramolecular contacts involving
protein residues are also analyzed with the help of the SVM-
RFE model, it becomes clear that a more indirect mechanism
of enzyme inhibition involving extensive conformational
changes within the protein structure operates under the
hood. Interactions at the S2 subpocket seem to be behind
conformational changes occurring on the right wall of the
binding cleft, while interactions at the S3 subsite mostly drive
conformational changes on the left wall. Both conformational
changes ultimately lead to rearrangements of residues at the
S1′ subsite that allows the proper positioning of the vinyl
sulfone warhead, which in turn allows the formation of key
backbone−backbone interactions between the inhibitor and
binding cleft wall residues.
Moreover, residue rearrangements at the S1′ subsite in
complexes of most active inhibitors involve the formation of
hydrogen bonds among residues of the catalytic triad that are
considered as a hallmark of the substrate recognition event.
This means that these high-affinity inhibitors are likely
recognized by the enzyme as if they were its own substrate
so that the catalytic machinery is arranged as if it is about to
break the substrate scissile bond.
2. RESULTS AND DISCUSSION
2.1. Compilation of a Structural Library of Cz−Inh
Complexes with Activity Annotations. Table 1 shows the
inhibition constants against Cz of P2/P3-modified vinyl
sulfones reported by Jaishankar,8 while Scheme 1 shows
substitution sites in vinyl sulfone analogues.
The crystal structure of Cz bound to the vinyl sulfone
inhibitor K-777 (PDB ID 2OZ2) provides the structural basis
for understanding inhibition of cruzain by vinyl sulfone
Table 1. Cz Inhibition by Vinyl Sulfone Analogues Reported
by Jaishankara8
compoundb R X Ar Ki (nM)
9d 4-Me CH DHBD 19
7d 4-Me CH 4-CF3Ph 45
6b 3-Me CH 3,5-DiFPh 50
9b 3-Me CH DHBD 71
9a H CH DHBD 80
7b 3-Me CH 4-CF3Ph 92
7a H CH 4-CF3Ph 97
8c 3-CF3 CH 2-pyridyl 150
4c 3-CF3 CH N-MePip 170
4a (K-777) H CH N-MePip 220
8a H CH 2-pyridyl 250
8b 3-Me CH 2-pyridyl 280
6d 4-Me CH 3,5-DiFPh 350
6a H CH 3,5-DiFPh 980
8d 4-Me CH 2-pyridyl 1700
4b 3-Me CH N-MePip 3300
4e H N N-MePip 3600
aN-MePip: N-methyl piperazine; DHBD: 2,3-dihydro-1,4-benzodiox-
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inhibitors.21 Taking that structure as a template, complexes of
Cz with the 17 vinyl sulfone analogues listed in Table 1 were
built manually and then refined by performing MD
simulations, as described in computational methods.
Naming letters (a, b, c, d, and e) and numbers (4, 6, 7, 8,
and 9) represent compound series obtained by varying P2 and
P3, respectively.
2.2. Local Electron Charge Density As the Descriptor
of Molecular Interactions in Cz−Inh Complexes. To
describe the molecular interactions in the modeled Cz−
inhibitor complexes, the charge density topological analysis in
the framework of the QTAIM was performed over the refined
complexes.
Briefly, this analysis basically consists of the mapping of the
gradient vector field onto the precomputed charge density of
the complex, ∇ρ. From this mapping, the charge density
topological element arises. Among the topological elements, an
interaction BCP and the BPs, which connect it to the
interacting atoms, are unequivocal indicators of the existence
of a bonding interaction.
As an example, Figure 1 depicts the BPs and BCPs
associated to the noncovalent interactions (Cz−Inh as well
as Cz−Cz and Inh−Inh interactions) in one of the complexes
studied here.
2.3. Training an Interaction Classifier Based on the
Charge Density Data. At this point, we have at our disposal,
the topological elements of the charge density describing the
interactions in the Cz−Inh complexes and the activity data
associated to the corresponding inhibitors.
Our goal is to take advantage of these data to find out
favorable interactions (to stabilize the complex), which might
explain the greater binding affinity of the more active inhibitors
and the unfavorable (or less favorable) interactions that
dominate the binding of the less active ones.
QTAIM analysis on biomolecular complexes often gives rise
to very dense and complex networks of interactions. By
inspecting Figure 1, it becomes evident that a comparative
analysis of such intricate network of interactions for a set of
Cz−Inh complexes cannot be performed by visual inspection
of the molecular graphs by a human operator. If so, a lot of the
information “hidden” under the charge density data would be
overlooked.
Instead, in this work, we have applied machine learning tools
to automate the process of extracting information from charge
density molecular graphs and to exhaustively exploit the charge
density data.
As explained by Fujita,22 depending on the particular type of
scientific question that needs to be answered, the predictive
model can be more or less complex. Relatively simple linear
models are more easily interpretable in terms of molecular
interactions although their predictive power is limited. More
complex nonlinear models have greater predictive power but
are more obscure or less interpretable.
In our case, our main interest was to shed light on the
interactions implicated in the enzyme action mechanism by
using a linear supervised model based on the complex
interactions and their corresponding inhibitory activities.
Moreover, data sets where there are fewer observed entities
than variables are becoming increasingly frequent, thanks to
the growing ease of observing variables, together with the high
cost of repeating observations in some contexts (e.g., DNA
microarrays).23 For example, Guyon24 has built an SVM
classifier to select a subset of genes biologically relevant to
cancer from broad patterns of gene expression data, recorded
on DNA microarrays. They used a relatively small number of
training examples from cancer and normal patients.
It is well known that when the number of features is large
and the number of training examples is comparatively small (as
in the case of ref 24 and in our case), the risk of overfitting
arises.
The overfitting problem can be reduced by measuring the
feature importance and selecting the most discriminative
feature subset. Elimination of redundant or irrelevant features
can improve the model accuracy, the generalization capacity,
and even the computational cost in some cases.25
SVM is a classification technique that uses support vectors to
maximize the distance between the two classes. The
coefficients of the model represent the vector coordinates
Scheme 1. Vinyl Sulfone with Its Substitution Sites Named
Ar, R, and Xa
aInhibitor parts that bind to S1, S1′, S2, and S3 enzyme subpockets
are named P1, P1′, P2, and P3, respectively.
Figure 1. View of the intricate networks of interactions on the
structure of the Cz−9d complex. Charge density topological elements
describing the noncovalent interactions are depicted with small red
circles (BCPs) and yellow lines connecting each BCP to both
interacting atoms (BPs). Both intermolecular (Cz−Inh) and intra-
molecular (Cz−Cz and Inh−Inh) interactions are considered. The
protein structure is depicted in the cartoon representation (A) and
surface representation (B), where each surface color represents a
different subpocket within the Cz binding cleft.
ACS Omega Article
DOI: 10.1021/acsomega.9b01934
ACS Omega XXXX, XXX, XXX−XXX
C
which are orthogonal to the hyperplane, and their direction
indicates the predicted class. The absolute size of the
coefficients (weights) can then be used to determine the
feature importance for the data separation task.24
On the other hand, SVM-RFE is a backward feature
selection algorithm based on SVM. SVM-RFE has been widely
applied in many fields including genomics, proteomics,
metabolomics, and other situations, where the data present a
large number of features, and the samples are scarce.26
RFE begins with the entire set of features, creates the SVM
model, and evaluates the accuracy. The least important
predictors are erased, and the model is computed again.27
In this work, an SVM-RFE model was trained with the
QTAIM-derived charge density information about molecular
interactions from the 17 Cz−Inh complexes to select relevant
features for the classification task, which might help to
understand the enzyme action mechanism. Inhibitors were
labeled as actives or inactives according to a decision threshold
value of 170 nM of inhibitory activity, which ensures balanced
classes.
SVM-RFE was built with a data set containing 319
interactions at the beginning, and then, the less relevant
features were iteratively eliminated by a backward selection
procedure.
The analysis of features that contribute to predictions only
makes sense if the model reaches a reasonably high-
performance level. Therefore, to monitor the accuracy of the
model during the backward elimination of features, stratified
two fold cross-validation was performed. In stratified cross-
validation, the class distribution of each fold is preserved for
the entire data set.28
Figure 2 shows the cross-validation mean accuracy of the
model as a function of the number of features selected by the
SVM-RFE procedure. Also, the variance of the accuracy among
the folds is depicted.
As can be seen in the figure, the mean accuracy of the model
rises as the number of features drops up to 87, when the
maximum performance is reached (87.75%). Also, note that
the variance of the accuracy among the two folds decreases to a
minimum value on the plateau region between ∼20 and 87
features.
Below ∼20 features, the mean accuracy starts decreasing
again, thus indicating that the classification model becomes too
simple as to discriminate between compounds from active and
inactive classes.
Therefore, for subsequent analysis of relevant features, we
selected the SVM model trained with a subset of the best 87
features because further reduction of the number of features
does not imply an increase in model performance.
The bar plot in Figure 3 shows the top interactions
(features) that were used by the final model to make the
classifications. Only feature coefficients with absolute values
greater than 2.0 are depicted in the figure.
The total height of stacked bars in Figure 3 represents the
interaction importance for the classification task while each
category within the bar represents the charge density
contribution of the two classes (active and inactive in orange
and light blue, respectively) to the overall feature importance.
As can be seen in the figure, interactions with positive
coefficients have overall greater contributions from compounds
labeled as actives while the opposite is true for interactions
with negative model coefficients, namely, their most important
contributions come from compounds labeled as inactives.
Therefore, by using a simple and interpretable linear SVM
classification model coupled with an RFE procedure, it is
possible to extract useful information about what are the most
important interactions to discriminate between active and
inactive (or less active) compounds against Cz.
2.4. Interaction-Based Correlation Matrix from
Charge Density Data. Although the trained classification
model helps recovering the relevant interactions from charge
density molecular graphs of Cz−Inh complexes, it does not
necessarily provide information about how these interactions
come into play together, namely, how they correlate to each
other to bring the enzyme into a particular conformational
state.
Different inhibitors might form different interactions which
in turn might stabilize different conformational states of the
enzyme. We wanted to know whether there could be a
relationship between compound activity against Cz and the
enzyme conformation stabilized. This information could be
very useful to choose the appropriate target structure in future
structure-based virtual screening campaigns.
Accordingly, the correlation matrix describing how inter-
actions are related to each other among the Cz−Inh complexes
was computed from charge density data (Figure 4). Only
interactions with importance greater than 2.0 in the SVM
classifier were considered for the correlation analysis.
Figure 4 shows that there is a clear anticorrelation (i.e.,
negative value) between active-like and inactive-like inter-
actions, namely, between interactions that prevail in complexes
of compounds labeled as actives and inactives, respectively.
This means that as the first interactions become stronger, the
last ones become weaker. This finding suggests that active and
inactive (less active) compounds stabilize different conforma-
tions of Cz.
2.5. Charge Density Molecular Graphs. Figure 5 shows
the structural superposition of complexes Cz−6b and Cz−8d
corresponding to compounds from active and inactive classes,
respectively. Interactions that are either formed/broken (or
just strengthened/weakened) in the comparison between both
complexes are depicted through their corresponding charge
Figure 2. Iterative process of backward feature elimination and SVM
model training with the remaining features. The mean accuracy of the
SVM model is depicted as a function of the number of features. Error
bars represent the variances of accuracy values among the folds.
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density topological elements (i.e., the BCPs and BPs). Charge
density values for the discussed interactions are shown in
Table S1 in the Supporting Information.
Among interactions that are prevalent in the most active
group of Cz inhibitors, H-bond N−H···OC between side
chains of protonated His162 and Asn182 at the S1′ enzyme
subsite is the most relevant one for the classification task,
according to the bar plot in Figure 3. This interaction can be
identified as interaction 1 in the molecular graph of Figure 5
and in the Figure 3 bar plot.
As it is well known, interaction 1 facilitates the formation of
the thiolate−imidazolium ion pair (Cys25)S−···+H−N-
(His162) necessary for catalysis.29,30 Therefore, it is remark-
able that this interaction is formed by compounds from the
active class, such as compound 6b, but not by compounds in
the inactive class, such as compound 8d. This means that
compounds labeled as actives better mimic the enzyme
substrate because they are able to accommodate the catalytic
machinery as if it were about to cleave the substrate scissile
bond.
In complexes of compounds from the inactive class, the
His162 side chain is displaced away from Asn182 and twisted
toward the inhibitor vinyl sulfone P1′ moiety forming a strong
(P1′)SO···+H−N(His162) interaction which is one of the
main features of the machine learning (ML) model among
compounds labeled as inactives (interaction 2 in Figures 3 and
5). In these complexes, a nearby indole ring from Trp184
Figure 3. Top interactions (features) selected by the SVM model to make the class classifications. The numbers in red indicate the interactions
discussed in the text.
Figure 4. Correlation matrix based on charge density data from interactions in Cz−Inh complexes.
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occupies the space where residues His162 and Asn182 are
going to interact in the active complexes.
Conversely, in complexes of compounds from the active
class, opposite changes are observed: interaction 2 is weakened
and His162 moves somewhat toward Asn182 to form
interaction 1.
However, before interaction 1 can be established, the
Trp184 ring must first vacate the region between residues
His162 and Asn182. In doing so, Trp moves away from
Asn182 and ends up right on top of the His162 ring where the
Trp electron cloud forms a C−H···π stacking interaction with
an His nonpolar hydrogen atom. This interaction, labeled as 3
in Figures 3 and 5, is also regarded by the SVM-RFE model as
one of the main interactions among the active class of
inhibitors.
We believe that these findings recovered with the help of an
ML model are meaningful because Trp184 is a highly
conserved residue among lysosomal cysteine proteases
belonging to papain superfamily, and it was previously
regarded as the “orchestrator” of the catalytic triad Cys25-
His162-Asn182 because it is believed that it plays a critical role
in the cleavage of the substrate by orienting the enzyme
catalytic machinery.30 Accordingly, based on our results and
previous findings, we propose that Trp184 might act as a
“switch” for interaction 1 formation.
Continuing with analysis of relevant interactions at the S1′
subsite, it can be seen in Figure 5 that the inhibitor sulfonic
group is held in place at the entrance of the S1′ subsite by two
strong O···H interactions between both sulfonic O atoms and
H atoms from the His162 imidazolium ring (interaction 2) and
Gln19 side chain amide group (interaction 4). Both
interactions are relevant features among the inactive class of
inhibitors as evidenced in Figure 3. This means that these
interactions are stronger in complexes of compounds from the
inactive class and either are broken or become weaker in
complexes of the active class.
It seems like when vinyl sulfones are strongly attached
through interactions 2 and 4 as in the case of compounds
labeled as inactives, the remaining inhibitor parts do not fit
well within the binding cleft, and so, they cannot establish
other important interactions that help to properly attach the
peptide-like backbone of the inhibitor. More concretely the
backbone of residues P1 and P2 from the inhibitor do not fit
properly into the narrow part of the binding cleft formed by
backbone atoms from the enzyme S1 subsite (see below).
For the inhibitor to fit well into the enzyme binding cleft, it
must be able to disturb the arrangement of residues within the
S1′ subsite. In other words, it must be able to either break or
weaken interactions 2 and 4 that hold firmly the vinyl sulfone
P1′ moiety at the entrance of the S1′ subpocket.
These rearrangements involve shifting of His162 toward
Ans182 and subsequent interaction 1 formation as explained
above (Figure 5). It also involves retraction of the Gln19 side
chain as discussed below. Rearrangements of the Gln19 side
chain can be more clearly seen in Figure 6 which shows the
structural superposition of complexes of compounds 9d and 4b
from the active and inactive class, respectively.
Depending on the complexes analyzed, some inhibitors from
the active class seem to push forward residues Gln19 and
His162 so that the vinyl sulfone P1′ moiety can penetrate a
little more deeply into the S1′ subsite (Figure 6). Thus, Gln19
and His162 might act as gatekeepers by selectively allowing the
entrance to the P1′ subsite to only the most active inhibitors.
After this rearrangement at the S1′ subsite, the backbone of
inhibitor residues P1 and P2 now fits well into the narrow
region of the binding cleft. This is evidenced by the
backbone−backbone interactions (P1)N−H···OC(Asp161),
(P2)CO···H−N(Gly66), and (P2)N−H···OC(Gly66)
which are formed or enhanced in complexes of compounds
labeled as actives and are some of the most relevant features
among the active class, according to the SVM-RFE model
(interactions 5, 6 and 7, respectively in Figures 3, 5, and 6).
These interactions are also considered as a hallmark of the
substrate recognition event in cysteine proteases.31 Also,
interaction (Cys25)S···H−N(Gly163) formation (interaction
8) helps to pull the inhibitor backbone (which is covalently
bound to Cys25) toward the bottom of the narrow region of
Figure 5. Structural superposition of Cz−6b (orange) and Cz−8d
(light blue) complexes. Charge density topological elements for
atomic interactions are also depicted: BPs connecting the nuclei are
depicted in orange and light blue for Cz−6b and Cz−8d, respectively.
BCPs are shown in small red spheres. Numbers in red indicate the
most significant interactions (the same as Figure 3). Arrows indicate
protein backbone displacement between Cz−8d and Cz−6b
complexes.
Figure 6. Structural superposition of Cz−9d (orange) and Cz−4b
(light blue) complexes. Charge density topological elements for
atomic interactions are also depicted: BPs connecting the nuclei are
depicted in orange and light blue for Cz−9d and Cz−4b, respectively.
BCPs are shown with small red spheres. Arrows indicate protein
backbone displacement between Cz−4b and Cz−9d complexes.




ACS Omega XXXX, XXX, XXX−XXX
F
the enzyme binding cleft, thus contributing to the overall
better fit of the inhibitor which is observed in complexes of the
most active compounds.
Because vinyl sulfone analogues reported by Jaishankar8
differ only in P2 and P3 residues, the explanation about why
some inhibitors are able to induce the required residue
rearrangements within the P1′ subsite and some other do not
must be related in some way to interactions they establish at
the S2/S3 subsites.
2.5.1. Interactions at the S3 SubSite. The P3 ring from
compounds labeled as actives and inactives interacts in
different ways with the key residue Leu67 at the S3 subsite
(see Figures 5 and 6). Compounds from the active class have
electron-rich groups at P3, and so, they tend to act as H-bond
acceptors against the side chain of Leu67. This is evidenced,
for example, by interactions such as Leu(67)C−H···π(P3) and
Leu(67)C−H···F(P3) in which the electron cloud or fluorine
lone pairs from the 3,5-difluorophenyl ring (compound 6b) act
as acceptors (Figure 5). In the other case, oxygen lone pairs
from the 2,3-dihydro-1,4-benzodioxin ring (compound 9d) act
as the H-bond acceptor in interaction Leu(67)C−H···O(P3)
(Figure 6). Unfortunately, these interactions are not recovered
by the SVM-RFE model (if so, the model would be overfitting
the charge density data) because there is no unique H-bond
pattern to Leu67 (i.e., there are different H-bond acceptors).
On the other hand, compounds from the inactive class have
electron-deficient P3 rings (2-pyridinium and N-methyl
piperazine in series 8 and 4, respectively, see Table 1), and
so, they only can form dihydrogen contacts with the Leu67
side chain, which are recovered by the ML model as one of the
most important features among complexes of compounds
labeled as inactives (interaction 9 in Figure 3).
From the mechanistic point of view, strong anchoring of the
P3 ring to the Leu67 side chain in complexes of active
compounds might pull the inhibitor toward the bottom of the
binding cleft, thus allowing formation of backbone−backbone
interaction 7 between the inhibitor P2 residue and Gly66,
(P2)N−H···OC(Gly66) (Figures 3, 5, and 6). As argued
above, interaction 7 formation, together with interactions 5, 6,
and 8, is an indicative of a good fit of the inhibitor backbone
within the enzyme binding cleft.
Besides this direct effect of P3 interaction with Leu67 on the
anchoring of the inhibitor backbone, there seems to be also an
indirect mechanism by which P3 interactions at the S3 subsite
influence the inhibitor binding mode.
In complexes of compounds labeled as actives, residues
Ser61 and Ser64 from the same loop as Leu67 (i.e., loop56−68)
form a CO···H−N H−bond which stabilizes a closed turn
between both residues. This (Ser61)CO···H−N(Ser64)
interaction (labeled as interaction 10 in Figures 3, 5, and 6)
is recovered by the SVM-RFE model as the second most
important feature among active-like interactions for the
classification of compounds labeled as actives/inactives based
on Ki values. It is likely that stability of interaction 10 is related
at least in part with the type of interactions that the inhibitor
P3 ring forms with the Leu67 side chain. An unstable
dihydrogen bond pattern between P3 and Leu67 (i.e., through
interaction 9) as in complexes of compounds labeled as
inactives might perturb conformation of the loop56−68, thus
leading to the observed breakage of interaction 10. Conversely,
stable H-bonds between P3 and Leu67 like in complexes of
compounds from the active class might help to hold more
firmly the loop, thus contributing to preserve the Ser61 →
Ser64 turn in its closed form.
Moreover, conformation of the Ser61 → Ser64 turn seems
to define how the loop56−68 is going to interact with the
surrounding protein structural elements like the nearby
loop11−23. In complexes of compounds from the inactive
class, there are several interactions recovered by the SVM-RFE
model as inactive-like interactions that might help to maintain
loops 56−68 and 11−23 close together (i.e., (Cys63)H···
N(Gly23), (Cys63)H···H(Gly23), and (Cys63)O···H(Gly23),
labeled as interactions 11, 12, and 13, respectively). On the
other hand, upon interaction 10 formation in complexes of
compounds from the active class, there is a conformational
rearrangement in the loop56−68 that somehow causes the
breaking of interactions 11, 12, and 13 that were holding both
loops together. As the loop11−23 moves away from the
loop56−68, the first loop drags side chain of Gln19 through an
interaction with the backbone of that loop (interaction 14,
Figures 3, 5, and 6). While Gln19 is dragged backward, its side
chain acquires a twisted conformation in which Gln19 gets
further apart from the inhibitor. As a consequence, interaction
4 between the Gln19 side chain and inhibitor sulfonyl oxygen
atom gets weakened. As discussed previously, rearrangement of
the Gln19 side chain seems to be critical for proper positioning
of the substrate within the Cz binding cleft and formation of
backbone interactions 5, 6, 7, and 8.
2.5.2. Interactions at the S2 SubPocket. Among all the
subsites that encompass the Cz binding cleft, the only one
which is deep enough to deserve the name of the subpocket is
S2. At the S2 subpocket, the anchoring of compounds from the
active class is mostly driven by π···H interactions between the
P2 ring electron cloud and nonpolar hydrogens donated by
Leu67 and Ala138 residues at both sides of the subpocket.
These interactions, named 15 and 16, respectively, have been
selected by the SVM-RFE model as important features among
compounds labeled as actives (see Figures 3, 5, and 6). On the
other hand, compounds from the inactive class either do not
form interactions 15 and 16 or they are much weaker. Instead,
the P2 ring from these compounds forms dihydrogen contacts
with Leu67 (interaction 17) which highlights the misplace-
ment of the P2 ring within the S2 subpocket.
Bringing together interactions analyzed for P2 and P3
residues, it is evident that Leu67 plays a key role in proper
anchoring of both residues to the Cz binding cleft.
Figure 7 shows the structural superposition of complexes of
compounds 6b and 6a from active and inactive classes,
respectively. These compounds only differ in the substituent at
the P2 residue, and so, they are suitable for studying
differences in interaction patterns that can be directly
attributed to the P2 structure.
Besides driving interactions with Leu67 and Ala138, most
active compounds also form other interactions that it is worth
noting. Thus, for example, interaction (P2)H···H(Glu208)
between two nonpolar H atoms from P2 and Glu208 side
chains, respectively, was selected by the SVM-RFE model as a
relevant feature among inhibitors from the active class
(interaction 18 in Figures 3 and 7). Glu208 lies at the bottom
of the S2 subpocket; hence, interaction of inhibitors from the
active class with that residue indicates that they are able to
reach such a distal region of the S2 subsite while inhibitors
from the inactive class, in general, are not.
Close to Glu208, there is another residue, Leu160, which is
also targeted by most active inhibitors through dihydrogen
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interactions (P2)H···H(Leu160) which are also recovered by
the ML model as a relevant feature among complexes of
compounds labeled as actives (interaction 19 in Figures 3 and
7).
It is unlikely that attractive forces would be behind
formation of these dihydrogen interactions as they are more
suggestive of steric crashes between hydrophobic atoms from
the ligand and enzyme. These subtle dihydrogen crashes
usually are the footprints left by stronger repulsive forces that
have been alleviated by displacements of the involved residues.
Therefore, by inspecting these dihydrogen interactions, one
can track back residue translocations or conformation changes
that might have happened as a consequence of a former
stronger steric crash. In particular, dihydrogen interactions 18
and 19 are the footprints of Glu208 and Leu160 side chain
displacements, respectively, induced by substituents at the 3 or
4 position of the inhibitor P2 ring (see Table 1). In contrast,
compounds that do not bear a substituent on the P2 ring, most
of them belonging to the inactive class, do not reach the distal
wall/bottom of the S2 subsite, and so, they do not form
interactions 18 and 19. These interactions and in particular
Figure 7. Structural superposition of Cz−6b (orange) and Cz−6a
(light blue) complexes. Charge density topological elements for
atomic interactions are also depicted: BPs connecting the nuclei are
depicted in orange and light blue for Cz−6b and Cz−6a, respectively.
BCPs are shown with small red spheres. Arrows indicate protein
backbone displacement between Cz−6b and Cz−6a complexes.
Figure 8. Distance histograms for selected interactions from complexes Cz−6b (orange) and Cz−8d (cyan). Also, the histogram for the Gln19 side
chain torsional angle is depicted. Distances corresponding to interaction 1 were measured between the center of mass of the involved residues.
ACS Omega Article
DOI: 10.1021/acsomega.9b01934
ACS Omega XXXX, XXX, XXX−XXX
H
interaction 19 seem to be related with residue rearrangements
at the S1 and S1′ subsites. As the substituent at the P2 ring
pushes away the side chain of Leu160, it also perturbs
backbone interactions between the nearby β-sheet161−170 and
β-sheet135−139 that are interacting in a hairpin-like motif. As a
consequence, the backbone of the β-sheet161−170 is partially
“released” and residues at the end of that sheet, that is, Asp161,
His162, and Gly163 experience a concerted backward
movement that place them in a proper position as to form
interactions 5 and 8 at the S1 subsite and triggers
rearrangements at the S1′ subsite involving His162 that
ultimately leads to formation of interaction 1, as discussed
previously.
Taking together the inhibitor interactions at the S2
subpocket and S3 subsite, the first ones seem to govern the
conformational changes occurring on the right wall of the
binding cleft (i.e., those involving the β-sheet161−170), while P3
residue interactions at the S3 subsite mostly drive the
conformational changes on the left wall (i.e., those related to
the loop56−68). Both conformational changes ultimately lead to
rearrangements of residues His162 and Gln19 at the S1′ site
that allows the proper positioning of the vinyl sulfone warhead
which in turn promotes formation of backbone−backbone
interactions between the inhibitor and the binding cleft wall
that are critical for inhibition.
Nevertheless, it should be kept in mind that the dissection of
the inhibition mechanism problem by protein subsites might
be an oversimplification because interactions at different
subsites might be related to each other, namely, the
conformational changes observed might depend not only on
the substituents at P2 and P3 but also on the combination of
both.
2.6. Two End-State Conformational Model for Cz
Supported by MD Simulations. In Section 2.3, we
separated interactions that are more prevalent in complexes
of most active inhibitors (i.e., active-like interactions) from
those that are more common in complexes of compounds from
the inactive class (i.e., inactive-like interactions). Then, in
Section 2.4, through the correlation analysis, we took a step
further to conclude that active-like and inactive-like
interactions stabilize two opposite conformations of the
enzyme.
To further support this hypothesis, we looked at some
active-like and inactive-like interactions along the MD
trajectories of Cz−Inh complexes.
Figure 8 depicts distance histograms from MD simulations
of complexes Cz−6b and Cz−8d corresponding to several
interactions regarded by the SVM-RFE model as important
features for stabilization of either active or inactive end-state
enzyme conformations. Also, a histogram for the Gln19 side
chain torsional angle is depicted.
As evidenced in Figure 8, several interactions show a
bimodal distribution of frequencies in which they are either
formed or broken, which is in agreement with the two end-
state conformational model proposed based on charge density
analysis of selected structures from different MD simulations.
Distance distribution of interaction 1 in complex Cz−8d
makes evident the two conformational states of residue
His162. In that complex, His162 is roughly half of the time
far away from Asn182 as in Cz conformation stabilized by less
active inhibitors. On the other hand, in complex Cz−6b,
His162 is close to Asn182 during the entire simulation time,
thus favoring interaction 1 formation as in the conformation
stabilized by most active Cz inhibitors.
Moreover, interaction 10 which is involved in loop56−68
conformation is formed most of the time of the simulation in
complex Cz−6b, thus stabilizing the closed form of the loop,
whereas, the same interactions are mainly broken during the
simulation of the Cz−8d complex.
As discussed previously, as a consequence of the loop56−68
re-organization on going from complex of less active to most
active Cz inhibitors, the loop11−23 is also displaced upward and
drags with it the Gln19 side chain through interaction 14 (not
shown). Concretely, the dragging motion involves the twisting
of the Gln19 side chain which is evidenced by the bimodal
population of the χ3 torsion angle where the twisted
conformation is represented by the distribution around 40°.
It can be seen in Figure 8 that the Gln19 side chain remains
more time twisted in complex Cz−6b than in Cz−8d.
Regarding interaction 4 between the Gln19 side chain amide
and inhibitor sulfonyl oxygen atom, it remains formed all the
time of simulations. However, the distance distribution is
slightly displaced toward largest interaction distances in
complex Cz−6b, which is likely a consequence of the lasting
Gln19 side chain twisting that place it further apart from
sulfonyl oxygens. As discussed previously, the weakening of
interaction 4 might contribute to the overall better fit of the
inhibitor within the Cz binding cleft.
Finally, distance distributions corresponding to backbone−
backbone interactions 7 and 5 show that 6b is more firmly
attached than 8d to the backbone of Gly66 and Asp161,
Figure 9. Sum of the charge density values at the BCPs due to intra−intermolecular interactions in Cz−inhibitor complexes. Values are partitioned
into four contributions corresponding to subpockets S1 (blue), S1′ (green), S2 (orange), and S3 (red). From left to right, complexes are ordered in
increasing values of Ki. Complexes are divided, with a dotted line, into two groups according to the decision threshold value (Ki 170 nM) used in
the SVM section. The compound nomenclature was extracted from Jaishankar.8
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respectively, which is also in line with the previous charge
density analysis on selected structures from different MD
simulations.
2.7. SubPocket Decomposition of the Binding
Affinity. Because charge density, as measured at the
interaction critical point, is a local topological property, we
can compute the contribution of a subset of such charge
density values to the inhibitor total anchoring strength. In that
way, we could know on which of the enzyme subpockets, the
interactions with the inhibitor need to be improved.
Figure 9 shows the decomposition of the charge density
values at the BCPs in Cz−Inh complexes by subpockets.
As can be seen in Figure 9, on going from the less active
inhibitors to the most active ones, the inhibitor anchoring
strength gets improved not in a particular subpocket but on all
the enzyme subpockets. This finding is in line with our
previous results. We have seen that substitution at P2 and P3
positions of the inhibitor not only induce changes in the S3
and S2 enzyme subpockets but also the entire enzyme binding
cleft is aware of such substitutions. This strong communication
between the different enzyme subpockets anticipates that the
optimization of interactions separately on each of the enzyme
subpockets might be difficult to achieve. Similarly, a fragment-
based approach for drug design would also be challenging for
the same reason. In a fragment-based pipeline, for discovery of
novel Cz inhibitors, one would presumably start with a small
fragment able to bind to the S2 subpocket (i.e., the easiest
subpocket to target) and from there it would have to be
enlarged toward the neighbor subpockets either by the
fragment-growing or fragment-linking approach. Because of
the strong inter-relationship between subpockets that we have
shown throughout this work, there is no guarantee that on
growing the S2 fragment toward S3, for example, the former
interactions at S2 would be maintained.
3. CONCLUSIONS
In this work, we have calculated, analyzed, and summarized
molecular interactions that arise from quantum calculations on
complexes of Cz with 17 known inhibitors at the Cz binding
site where the analysis of activity differences in terms of
molecular interactions at the Cz binding cleft has not been
described yet.
QTAIM provided topological elements of the charge density
that describe the interactions in the Cz−Inh complexes. At this
point, with more than three hundred interactions per complex,
we trained a supervised learning classification model with RFE
that discriminates between interactions present in complexes
of the most-active inhibitors (active-like interactions) and
those that occur in the less-active ones (inactive-like
interactions). Moreover, the model also provided information
about the interaction importances, namely, which are the most
important interactions to discriminate between complexes of
active and inactive (or less active) compounds against Cz.
Our model allowed us to point out 19 inter-/intramolecular
main interactions that could explain the principal changes in
the complexes under analysis.
Among the intermolecular interactions, backbone−back-
bone interactions 5, 6, 7, and 8 as well as interactions of
inhibitor residues P2 and P3 with the Leu67 side chain play a
key role in proper anchoring of most active inhibitors into the
enzyme binding cleft. Unfortunately, no quantitative relation-
ship was found between the structure and activity data when
considering only intermolecular interactions.
By taking into account also intramolecular interactions and
with the help of the SVM-RFE model to separate active-like
from inactive-like interactions, a more indirect mechanism of
enzyme inhibition involving extensive conformational changes
within protein structure arises.
These protein conformational changes occur on both “walls”
of the binding cleft promoted by intermolecular interactions at
the S2 and S3 sites. Inhibitor interactions at the S2 subpocket
trigger conformational changes on the β-sheet161−170 (right
wall), while interactions at the S3 subsite mostly drive
conformational changes on the loop56−68 (left wall). Both
conformational changes ultimately lead to re-arrangements of
residues His162 and Gln19 at the S1′ site that allows proper
positioning of the vinyl sulfone warhead and formation of key
backbone−backbone interactions between the peptide-like
inhibitor and binding cleft wall residues.
On the other hand, our study also allowed us to understand
how important the role of the highly-conserved Trp184 is,
enabling interaction 1 formation that leads to activation of the
catalytic histidine. The “switching activity” of Trp184 is crucial
for accommodation of the catalytic triad. Different interactions
“orchestrated” by this residue determine activation/inactiva-
tion of the protein machinery.
In this regard, we have found that most active Cz inhibitors
induce a conformation in which interactions considered as a
hallmark of the substrate recognition event are present. Having
isolated this “activated” Cz structure, we can use it in rigid
docking experiments in the context of prospective virtual
screening campaigns to “fish” highly active Cz inhibitors from
compound databases.
Moreover, among relevant interactions that stabilize the
“activated” Cz conformation, intermolecular interactions such
as 5, 6, and 7 could be plugged into the docking algorithms to
customize the scoring function and guide the docking
predictions.
Finally, throughout this study, we also got a sense of the
strong communication that exists between the enzyme binding
cleft subpockets, the property that might help us to choose the
best approach to follow in prospective screening campaigns.
Probably a fragment-based approach is not the best choice in
this case because of this property of high inter-relationship
between subpockets.
All the collected information would be taken into account in
the following prospective studies aimed to search novel Cz
inhibitors.
4. COMPUTATIONAL DETAILS
4.1. Simulation Protocol. Jaishankar8 synthesized and
determined the inhibition constants against Cz of a series of
vinyl sulfone analogues closely related to K-777.
Although the experimental structure of these vinyl sulfone
analogues in the complex with Cz has not been determined yet
(except for K-777, pdb id = 2OZ2), for peptide-like Cz
inhibitors, a reasonably accurate initial guess of the inhibitor
binding mode can be constructed “by hand” by placing each
residue in the inhibitor sequence P1′, P1, P2, and P3 into its
own enzyme subpockets S1′, S1, S2, and S3.
Initial coordinates of the complex were taken from the
structure of Cz bound to K-777 (pdb id = 2OZ2).21 By
performing substitutions at P2 and P3 residues of K-777 to get
the analogues reported by Jaishankar,8 17 closely related
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All the Cz−inhibitor complex simulations were carried out
with Amber14 software package32,33 at 300 K temperature and
extended up to 50 ns overall simulation time in a truncated
octahedral periodic box of TIP3P water molecules. Amber
ff14SB force field was used for proteins residues.34 The
antechamber software in the Amber-Tools package was used to
generate ligand inhibitor parameters with GAFF force field and
RESP charges.35
4.2. Quantum Theory of Atoms in Molecules. The
structure of the potential energy minimum was selected from
the MD trajectories of Cz−Inh complexes as a single
representative structure upon which the charge density analysis
was done.
Because accurate quantum mechanical calculations are still
forbidden for full biomolecular complexes, reduced models
were constructed from the potential energy minimum
structures. A total of 28 residues (∼570 atoms) were included
in the reduced models: the vinyl sulfone inhibitor and the
surrounding residues in a spherical volume of about 5 Å
centered on the inhibitor atoms (Figure S1 in the Supporting
Information shows the residues included in the reduced
models).
The charge density was computed by density functional
theory methodology with the M06-2x dispersion corrected
hybrid functional and 6-31G(d) as the basis set, as
implemented in Gaussian 09 package.36 The topological
analysis of charge density was then performed with Multiwfn
software.37
4.3. Support Vector Machines−Recursive Feature
Elimination. Charge density values associated to 319
noncovalent interactions per complex were used as features
to train a linear SVM classifier. SVMs are supervised learning
models with associated learning algorithms that analyze data
used for classification and regression analysis.38
If the data are not separable by a hyperplane, they can be
mapped into feature spaces of higher dimensionality where
linear separation of positive and negative examples might be
possible (i.e., the so-called kernel trick). However, unlike linear
models, SVM models trained on high-dimensional kernel
spaces have black box character, and it is generally difficult to
rationalize model performance.39 Therefore, in this article, we
restricted ourselves to linear SVM because our main interest
was in uncovering relationships between the features (i.e.,
molecular interactions) and the biological activities to
understand, ultimately, the enzyme inhibition mechanism.
Nevertheless, it is important to bear in mind that the analysis
of features that contribute to predictions only makes sense if
the model reaches a reasonably high-performance level.
It is well known that when the number of features is large
and the number of training examples is comparatively small,
the risk of overfitting arises. Therefore, to overcome the
problem of high dimensionality and scarce samples of our data
set, SVM was coupled with the RFE algorithm during model
training.
SVM-RFE is a feature selection algorithm based on
backward elimination of features with lowest weights. In
each iteration, the SVM model is trained with the current
subset of features, the weight (|w|) of each feature is calculated
according to the SVM classifier, the features are ranked
according to |w|, and then, the bottom-ranked features are
eliminated.26
SVM-RFE and stratified twofold cross-validation were
implemented with the help of the scikit-learn module of
Python.40
4.4. Dynamic Cross-Correlation Analysis. The correla-
tion matrix describing how interactions are related to each
other among the Cz−Inh complexes was computed from
charge density data obtained from QTAIM calculations. Only
interactions with importances greater than 2.0 in the SVM-
RFE classifier were considered for the correlation analysis.
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